The first phase of the Houston convention district's transformation includes the addition of GRB South, a new 700,000-square-foot convention facility. Rendering courtesy Houston First.

Mayor John Whitmire and Houston First Corporation shared a new master plan for the George R. Brown Convention Center and its surrounding area last week. The plan features expanded exhibition space, a living roof, a pedestrian plaza with access to Toyota Center and more.

The project will be funded by the state’s portion of incremental Hotel Occupancy Tax revenue growth within a three-mile radius of the GRB for 30 years, which is estimated to total about $2 billion, according to a release from Houston First.

The first phase of the project, which is slated to be completed by 2028, will focus on developing a 700,000-square-foot convention facility known as GRB South.

GRB South will feature:

  • Two exhibition halls, totaling 150,000 square feet
  • A 50,000-square-foot multipurpose hall that opens to the new Central Plaza
  • The 100,000-square-foot Central Plaza, an extension of the Avenida Plaza that will connect to Discovery Green and Toyota Center
  • Atrium flex hall totaling 25,000 square feet
  • 225,000 square feet of contiguous exhibit space
  • A 60,000-80,000-square-foot ballroom
  • Ground-level spaces for retail and restaurants
  • A central atrium, providing each level with natural light

The design of the space is inspired by the Houston area's native prairies and will use low-carbon materials, high-efficiency building systems with rainwater collection and water-reduction strategies. A living roof on top of the GRB South will also have the potential for solar integration.

"It is imperative for us to stay competitive and meet the needs of our meetings and convention customers,” Michael Heckman, president and CEO of Houston First, said in the release. “This project will not only accomplish that but will establish a gathering space that will be the epicenter for entertainment, sports, and city-wide events, accentuating our ability to capitalize on Houston's unique offerings.”

The full campus renovation is expected to wrap in 2038, and construction will be managed in phases. Houston First reports that construction should not impact events currently scheduled as GRB.

“This project is truly transformative for downtown Houston, a lasting legacy that will solidify our position as a top-tier convention and entertainment destination,” Mayor John Whitmire said in the release. “Most importantly, we are creating a space that will build community, foster connection, and shape the future of Houston.”

Explore renderings of the plans below.

Rendering courtesy Houston First.

Created by Italian art studio Quiet Ensemble, Solar Dust comes to Houston via Austria. Photo via posthtx.com

Innovative Italian art installation illuminates downtown Houston development

lights show

Experiencing art is no longer about just looking at paintings on a wall or sculptures on a stand. It's also about being immersed in the works, seeing them from all sides.

That's exactly what Solar Dust offers. The new immersive work will make its U.S. debut at POST Houston's Art Club, a black box art exhibition space and nightlife experience inside the downtown mixed-use development, food hall, and gathering spot.

Created by Italian art studio Quiet Ensemble, Solar Dust comes to Houston via Austria. Opening June 1, the pop-up exhibition features the immersive artwork exploring light, sound, and the interconnectedness of nature and technology.

In Solar Dust, state-of-the-art lasers fire at a mass of steel-filament tulle, animating an ever-shifting series of shadows that creates the illusion of suspended particles in space. Exhibit visitors are invited to contemplate the delicate balance between light and dark, sound and silence, order and chaos.

"We are thrilled about Solar Dust's US debut at POST in Houston, a global city renowned for its rich and diverse arts scene, which provides the perfect backdrop for our unconventional work,” said Nicolas Roziecki of Quiet Ensemble in a statement. “Solar Dust is not an immersive artwork; it's a captivating light installation that transforms an exhibition space into a celestial realm. We invite visitors and Houstonians alike to embark on this journey and immerse themselves in the allure of a three-dimensional glowing structure, evocative of celestial light dust."

In addition to showcasing the unique work, the pop-up exhibit also serves to introduce Houston to POST's Art Club concept, which officially debuts this fall in the venue's X Atrium. Expect a mash-up of programming and exhibits that borrow from nightclubs and art galleries. Sprawling across 40,000 square feet, the Art Club takes a fresh approach to limited-engagement installations by bringing a rotating roster of light and digital media artists and designers from around the world. The first season will be announced early this fall.

In the meantime, those wishing to see Solar Dust may do so for $7 via Eventbrite.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”